Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection – a potential curative medicine. sd-rxRNA therapeutics can be used as a standalone treatment or in combination with other modalities. Our development strategy is to tackle different immune escape mechanisms to treat solid tumors in three main areas:
- Boosting immune cell function
- Boosting immune effector cell fitness and persistence, and
- Increasing tumor cell recognition and immunotherapy susceptibility
Essentially, we aim to maximize the power of our sd-rxRNA therapeutic compounds by weaponizing therapeutic immune effector cells to attack cancer and ultimately provide patients battling terminal cancers with a powerful new treatment option that goes beyond current treatment modalities.